

Index

- 5-aza-2-deoxycytidine (decitabine; Dacogen, Supergen) therapy 189
- 5-azacitidine (5-AzaC; Vidaza, Pharmion) therapy 189
- 5q-syndrome 3–5, 17 *see also* chromosome 5 abnormalities
 - diagnosis and prognosis 38, 108
 - molecular analysis 109–10
 - morphologic correlates 43
 - prognosis 8–9
 - underlying genetic defects 132
 - WHO classification 3–5, 40
- AA (aplastic anemia) 5, 44–5 *see also* SAA (severe aplastic anemia)
 - 7/del(7q) linked to immunosuppressive treatment 110–11
 - clinical trials of rTPO (rMGDF) 226
- abnormal clones, evolution of 99–100
- aCML (atypical chronic myeloid leukemia) 45–6, 49
- acute myeloid leukemia *see* AML
- AG13736, RTK inhibitor 182–3, 184
- AG3340 (Prinomastat), selective inhibitor of MMPs 182–4
- aging
 - accumulated oxidative stress damage 65, 68–9, 81–2
 - increasing incidence of hematologic malignancies 65, 68–9, 81–2
- ALIP (atypical localization of immature precursors) 9
- and medullary angiogenesis 179–80
- and VEGF 66–7
- prognostic feature 17, 18
- alkylating agent and/or radiation-related MDS 43–4
- all-trans* retinoic acid and rEPO combined treatment 223
- amifostine
 - combined treatment with rEPO 223
 - hematopoiesis promoter 176–8
 - TNF- α inactivation studies 176–8
- AML (acute myeloid leukemia) *see also* t-AML (secondary/therapy-related AML)
 - AML-MDS 1
 - effects of translocations 115–16
 - evolution of MDS to or towards 63
 - FAB classification 1–3
 - levels of VEGF 66–7
 - myelonic clonogenic abnormalities similar to MDS 71–2
 - rate of hemopoietic cell apoptosis 73–4
 - WHO classification 3–5
- AML 1 gene mutations in MDS 134–5
- association with poor prognosis 77
- AML1/MDS1/EV11 (AME) leukemia-associated fusion gene 77
- anemia, aplastic *see* AA (aplastic anemia)
- anemia in MDS *see also* RA (refractory anemia)
 - influences on 71–2
 - supportive care for 209–10
- angiogenesis
 - MVD (microvascular density) as a prognostic feature 17, 18
 - role of VEGF 179–80, 185
 - to support growth of hematologic malignancies 66–7

- angiogenesis inhibitors 179–80, 181, 185
 - small-molecule inhibition of VEGF RTK 182–3, 184
 - antigens
 - autoantigen overexpression in MDS 155–7
 - cause of T-cell responses in MDS 155–7
 - APL (acute promyelocytic leukemia)
 - activity of ATO (arsenic trioxide, Trisenox) 184–5
 - effects of therapy 43–4
 - aplastic anemia *see* AA (aplastic anemia); SAA (severe aplastic anemia)
 - apoptosis
 - association with *fas* ligand production in MDS 213–14
 - changing rate as MDS progresses 68–9, 73–4
 - increase in MDS 100–3, 104
 - increase in MDS marrow 67–71
 - mechanisms and treatments in MDS 213–14
 - mediated by TNF- α 176–9
 - of hemopoietic precursors and their progeny in MDS 68–9, 72–4
 - rate in AML , 73–4
 - regulatory genes 68–9, 73–4
 - apoptosis-generating proteases (caspases) 67–71, 72–3
 - arsenic exposure, as cause of myelodysplasia 38–9
 - ATG (antithymocyte globulin)
 - clinical trials for immunosuppression in MDS 148, 158–60, 161
 - immunosuppressive effectiveness compared to CSA 156, 162–4
 - low leukemic progression among responders 157–8
 - PNH abnormality as favorable response factor 149–51
 - response in trisomy-8 disease 154–5
 - response to treatment in MDS 149
 - selection of likely responders 175–6
 - targeting hematopoietic inhibitory T lymphocytes 175–6
 - treatment of SAA 147–8
- ATO (arsenic trioxide, Trisenox)
 - activity in acute promyelocytic leukemia 184–5
 - antiproliferative effects in MDS and AML 184–5
- autoantigens, overexpression in MDS 155–7
- benzene, implication in leukemogenesis 5–6
- bevacisumab (Avastin), VEGF-A inhibitor 184
- BFU-E (burst forming unit-erythroid) cells in MDS and AML 210–11
- blasts, FAB-defining criteria 33
- blood transfusions *see* iron overload (transfusional); transfusion support in MDS
- bone marrow *see* marrow
- BU (busulfan), in HCT-conditioning regimens 247–51, 253
- c-mpl* (TPO receptors), reduced numbers in MDS 224–5
- c-mpl* ligand (thrombopoietin) *see* TPO
- cancer therapy, as cause of t-MDS/t-AML 97, 114–15, 116–17
- cardiac disease, due to iron overload 226–7, 231–2
- caspases (apoptosis-generating proteases) 67–71, 72–3
- CC-5013 (lenalidomide or Revlimid)
 - antiangiogenic properties 181–2
 - response of 5q– syndrome patients 8–9
- CD34+ cells
 - gene expression microarray analysis 136–7, 140, 141
 - prediction of MDS risk 139–40, 141
 - selection of differentially expressed genes 138–9
 - used to detect abnormalities 129–31
- CDSs (commonly deleted segments)
 - in 17p– syndrome 112
 - in del(5q) 109–10
 - in del(7q) 111–12
 - in del(20q) 106–7
- CFU-E (colony forming unit–erythroid) cells in MDS and AML 210–11
- CFU-GEMM (colony forming unit–granulocyte, erythroid, macrophage, megakaryocyte) cells, in MDS and AML 210–11
- CFU-GM (colony forming unit–granulocyte, macrophage) cells in MDS and AML 210–11
- CFU-Mk (colony forming unit–megakaryocyte) cells in MDS and AML 210–11

299 Index

- chemical exposure, as cause of
 - myelodysplasia 38–9
- chemotherapy
 - for high-risk MDS 188, 193
 - intensive therapy before HCT 246–8, 251, 252, 253
 - use of rTPO to reduce
 - thrombocytopenia 224–5
- chemotherapy-related MDS (t-MDS) 43–5, 255–6
- children *see* pediatric myelodysplastic syndromes
- chromosomal instability 78–9
- chromosome 1 abnormalities, 1q 17, 18
- chromosome 3 abnormalities, 3q
 - translocations 116–17
- chromosome 5 abnormalities 6 *see also*
 - 5q– syndrome
 - 5q chromosomal region abnormalities 75
 - associated conditions 132
- chromosome 5 loss or del(5q) *see also*
 - 5q– syndrome
 - identification of CDS 109–10
 - link with exposure to mutagens 107–8
 - possible locations of tumor suppressor genes 109–10
- chromosome 7 abnormalities 6
 - 7/del(7q) abnormalities in childhood MDS 97, 110–11
 - JMML and –7 chromosome abnormality 97, 110–11
 - monosomy 7 syndrome 97, 110–11
- chromosome 7 loss or del(7q)
 - identification of CDSs 111–12
 - link with exposure to mutagens 97, 107–8, 110–11
 - myeloid disorders associated with 97, 110–11
 - prognostic implications 97, 110–11
- chromosome 8 gain (+8) in MDS 110
 - trisomy 8 17, 18, 157–8
 - trisomy-8 disease 154–5, 156
- chromosome 11 abnormalities 113–14
 - 111q23 locus 6, 113
- chromosome 12 abnormalities
 - 12p syndrome, underlying genetic defects 133
 - del(12p) 17, 18
- chromosome 17 abnormalities
 - 17p deletion 20, 21–2
 - 17p– syndrome 112
- chromosome 20 abnormalities, del(20q) in MDS 106–7
- chromosome 21 abnormalities, 21q22 locus 6
- chromosome abnormalities 6, 20 *see also*
 - chromosome translocations; cytogenetic abnormalities in MDS
 - as prognostic features 11–12, 17
 - benzene-induced 5–6
 - chromosome deletions in MDS 74–5
 - frequency and types 96–8
 - molecular models 104–5
- chromosome translocations
 - 3q 116–17
 - MLL* gene 113–14
 - platelet-derived growth factor receptor- β 115–16
 - recurring 115–17
 - t(11;16) 113–14
- chronic myeloid leukemia 45–9
- chronic myelomonocytic leukemia *see* CMML
- ciprofloxacin, use in TNF- α inactivation studies 178
- clinicians, quality of information given to MDS patients 278–9
- clonal myeloid hemopathies, characteristics 63
- CMML (chronic myelomonocytic leukemia)
 - 3–5
 - association with 12p rearrangements 133
 - association with marrow fibrosis 44–5
 - effects of translocations 115–16
 - FAB classification 1–3, 33, 34, 47
 - imatinib activity and chromosome 5q33 translocations 185–6
 - myelodysplastic and myeloproliferative forms 46–9
 - prognostic risk groups (FAB) 7, 8
 - proliferative and non-proliferative subgroups 2–3
 - Ras* gene mutations 192–3
 - WHO classification 45–6, 47–8, 49
- CMML-1 47
- CMML-2 47
- congenital disorders, associated with MDS 38–9, 134–5

300 Index

- congenital neutropenia, associated with
MDS 134
- CSA (cyclosporin A)
 - clinical trials for immunosuppression in MDS 148, 161
 - immunosuppressive effectiveness compared to ATG 156, 162–4
 - targeting hematopoietic inhibitory T lymphocytes 175–6
 - therapy for high-risk MDS 187–8, 193
- CY (cyclophosphamide), use in
HCT-conditioning regimens 247–50, 251, 253
- cytarabine therapy, for high-risk MDS 186, 187–8, 193
- cytogenetic abnormalities in MDS 43 *see also*
 - chromosome abnormalities
 - 5q– syndrome 108
 - +8 (gain of chromosome 8) 110
 - 11q23 abnormalities 113
 - 17p– syndrome 112
 - complex karyotypes 114
 - del(20q) 106–7
 - implications for prognosis 96, 97–8
 - loss of chromosome 5 or del(5q) 107–8
 - loss of chromosome 7 or del(7q) 97, 110–11
 - molecular analysis of –7/del(7q) 111–12
 - molecular analysis of the del(5q) 109–10
 - morphologic correlates 43
 - normal karyotype 106
 - recurring translocations 115–17
 - role in MDS pathogenesis 74–5
 - scoring in IPSS for MDS 98, 99
 - t(11;16) translocation 113–14
 - Y (loss of Y chromosome) 106
- cytogenetic abnormalities in t-MDS 97, 114–15
- cytogenetic analysis
 - required for WHO classification
 - diagnosis 95–7
 - to confirm diagnosis 95–7
 - to define risk for progression to AML 95–7
 - to define the prognosis 95–7
 - use in diagnosis of MDS 96, 97–8
 - use in prognostic scoring systems 95–7
- cytogenetic risk groups 17, 18
- cytokine antagonists, clinical trials for
immunosuppression in MDS 162
- cytokine neutralization in MDS 178–9
- cytokine therapies for MDS 209–10
 - darbepoetin alfa 231
 - pegfilgrastim 231
- cytokines
 - combination treatments with TPO 224–5
 - decreased production in MDS 210–11
 - in the marrow microenvironment 64, 65–6
 - inhibitory cytokines and the p38 kinase signaling cascade 67, 68–9
 - proapoptotic cytokine overproduction in MDS 182–4
- cytotoxic agents, as cause of t-MDS/t-AML 97, 114–15, 116–17
- death, quality of care at the end of life 279
- decitabine (5-aza-2-deoxycytidine; Dacogen, Supergen) therapy 190
- deferiprone (L1, Ferriprox) iron chelator, clinical trials 229–30
- depsipeptide therapy, for high-risk MDS 190
- desferrioxamine (Desferal) iron chelator 209–10
 - treatment for transfusional iron overload 227–9
- dexamethasone, use in TNF- α inactivation studies 178
- diagnosis, implications of cytogenetic abnormalities 96, 97–8
- diagnosis of MDS, morphologic features used 39
 - blast percentage in blood and marrow 38
 - evaluation of myeloid cell lines 35
 - manifestations of dyserythropoiesis 35
 - manifestations of dysgranulopoiesis 38
 - megakaryocytic dysplasia 38
 - myelodysplasia not diagnostic of MDS 38–9
 - non-clonal etiologies of myelodysplasia 38–9
 - peripheral blood abnormalities 35
- differentiation agent therapies, for high-risk MDS 190–1
- DLI (donor lymphocyte infusion) therapy 256–7
- DLK1 (delta-like 1) gene, overexpression in MDS 138–41
- DMT (DNA methyltransferase) inhibitors 190
- DNA methylation
 - as cause of gene silencing 136
 - gene expression regulation 136

301 Index

- Down syndrome myeloid leukemia 51–2, 53
dysmyelopoietic syndrome 33
- epigenetic gene regulation therapies, for high-risk MDS 190
epigenetic hypermethylation, and loss of tumor suppressor gene expression 68–9, 74, 80–1
EPO (erythropoietin) *see also* rEPO
 in vitro effects on MDS erythroid progenitors 210–11
 in vitro synergistic effect with G-CSF 210–11
 mechanisms of action 213–14
 synergy with G-CSF 218–19, 220
Etanercept (Enbrel) recombinant soluble TNF- α , use in TNF- α inactivation studies 178–9
Ets family of transcription factors
 control of gene expression 68–9, 74, 78–9
 implication in myeloid malignancies 68–9, 74, 78–9
 roles in signaling pathways 68–9, 74, 78–9
EVII gene, possible role in leukemia induction 77
- FAB (French–American–British) morphologic classification of MDS 1–3, 33, 34, 37
 ambiguity in refractory anemia (RA) criteria 40–1
 CMML 47
 differences to WHO classification 40–2
 prognostic limitations 2–3
 RAEB-T (refractory anemia with excess blasts in transformation) 41–2
farnesyl transferase inhibitors (FTI) 100–4
 therapies for high-risk MDS 192–3, 195
fas-ligand production, association with apoptosis in MDS 213–14
fatigue, measurement of QOL effects in MDS 275–6, 277
FGF-receptor fusion genes 185–6
FISH (fluorescence in situ hybridization) 106–7
flt3 gene mutations, and high risk of transformation to AML 77
fludarabine, use in HCT-conditioning regimens 250–2, 253
fms mutations
 effects of 76
 transforming activity 76
 folate deficiency, as cause of myelodysplasia 38–9
 folic acid antagonists, as cause of myelodysplasia 38–9
FPD/AML (familial platelet disorder with predisposition to AML), associated with MDS 134–5
fusion genes 115–17
 AML1/MDS1/EVII (AME) leukemia-associated fusion gene 77
 FGF-receptor fusion genes 185–6
 MDS1/EVII fusion gene, possible role in leukemia induction 77
 PDF-receptor fusion genes 185–6
G-CSF (granulocyte colony-stimulating factor) *see also* rG-CSF
 as cause of myelodysplasia 38–9
 decreased levels in MDS 210–11
 in vitro effects on MDS cells 210–11
 in vitro synergistic effect with EPO 210–11
 mechanisms of action 213–14
 synergy with EPO 218–19, 220
gemtuzumab ozogamicin (Mylotarg) therapy, for high-risk MDS 186–7
gene expression alteration and disease progression 17, 20, 22–3
gene expression microarray analysis in MDS 136–7, 140, 141
 prediction of disease risk using CD34+ cells 139–40, 141
 selection of differentially expressed CD34+ genes 138–9
 technique 137–8
gene expression profiles, future directions 24–5
gene function
 alterations 100–3, 104
 mechanisms for loss of 104–5
gene mutation and disease progression 17, 20–3
 AML1 point mutations 17, 20, 23
 bcl2 17, 20, 22
 flt3/ITD (internal terminal duplication) 17, 20, 23
 fms 17, 20, 21
 ras 17, 20, 21
 Wilms tumor *WT1* 17, 20, 21–2
 p53 (*TP53*) 17, 20, 21–2

- gene silencing by hypermethylation 136
 - and leukemia transformation risk 68–9, 74, 80–1
 - in MDS and leukemias 68–9, 74, 80–1
 - reversal by DMT inhibitors 190
- genetic abnormalities
 - alterations most frequently found in MDS 129–31
 - association with specific syndromes in MDS 132–5
 - in cell cycle-related genes 135–6
 - in signal transduction-related genes 135–6
- genetic instability 78–9
- genomic instability
 - and abnormal telomere maintenance 68–9, 79–80
 - and clinical outcome 17, 23
- Gleevec *see* imatinib mesylate
- GM-CSF (granulocyte–macrophage colony-stimulating factor) *see also* rGM-CSF
 - decreased production in MDS 210–11
 - in vitro effects on MDS cells 210–11
- GvHD (graft-versus-host disease), following HCT for MDS 246, 247–8
- haploinsufficiency 105
- health-related quality of life *see* HRQOL
- heavy metal exposure, as cause of myelodysplasia 38–9
- HCT *see* hematopoietic cell transplantation
- hematopoiesis
 - HGF effects in in vitro MDS culture systems 210–11
 - ineffective 63
- hematopoietic cell transplantation (HCT) for MDS 243–4
 - accurate prognostic assessment 244–5
 - age of patient 244–5, 254
 - allogeneic transplants 245, 247–50, 253
 - autologous transplants 253
 - childhood MDS 254–5
 - damage caused by intensive conditioning schedules 255–6
 - donor availability 245, 247–50, 253
 - factors to be considered 244–5, 247
 - G-CSF-mobilized peripheral blood progenitor cells (PBPC) 247–8, 253
 - GvHD (graft-versus-host disease) 246, 247–8
 - IPSS score and choice of therapy 244–5
 - IPSS score and survival after HCT 243–4, 246
 - IPSS score and timing of therapy 246
 - irradiation and chemotherapy as cause of t-MDS 255–6
 - JMML 254–5
 - MDS risk level 244–5
 - “mini-transplants” 250–2, 253
 - myeloablative HCT for “advanced” MDS 248–50, 251
 - myeloablative HCT for “less advanced” MDS 244, 247–8
 - non-myeloablative (NMA) conditioning regimens 250–2, 253
 - outcomes of various conditioning regimens 244, 247–51, 252, 253
 - PBPC (peripheral blood progenitor cells) 247–8, 253
 - possible option for “older” patients 254
 - posttransplant relapse 256–7
 - posttransplant relapse risk 248–50, 251
 - pretransplant chemotherapy 246–8, 251, 252, 253
 - reduced-intensity conditioning (RIC) regimens 250–2, 253
 - relapse-free survival rates in relation to IPSS score 246
 - transplant strategies 244, 245, 247–8, 251, 252, 253
 - treatment for t-MDS 255–6
- hematopoietic growth factors *see* HGFs
- hematopoietic inhibitory T lymphocytes (HIT cells), immunosuppressive therapy 175–6
- hematopoietic regulatory interactions, and the marrow stromal microenvironment 63–4, 65, 66
- hematopoietic stem cells *see also* hemopoietic stem cells
 - characterization of defects in MDS 129–31
 - indications of immune-mediated response against 147–8
 - technical challenges in detection of abnormalities 129–31

303 **Index**

- use of CD34+ cells to detect abnormalities 129–31
- use of microarray technology to assess gene expression 131
- hemopoietic stem cells *see also* hematopoietic stem cells
 - abnormalities in genes regulating hemopoiesis 68–9, 74, 75–7, 78–9
 - alterations to signal transduction pathways 68–9, 74, 75–7, 78–9
 - anomalies 63
 - apoptosis of hemopoietic precursors and their progeny 68–9, 72–4
 - cytogenetic abnormalities 74–5
 - derivation from malignant myeloid clone in MDS 71–2
 - inherent abnormalities in MDS 65, 68–9, 71–4, 82
 - role of transcription factors in myeloid malignancies 68–9, 74, 78–9
- hemopoietic stem cell transplantation (HSCT) 19 *see also* hematopoietic cell transplantation (HCT)
- HGFs (hematopoietic growth factors) 209–10 *see also* rHGFs
 - defective production of 64–5
 - diminished production and responsiveness in MDS 210–11
 - in vitro effects on hematopoiesis in MDS 210–11
 - in vitro observations as platform for clinical testing 210–11
 - reduced responsiveness to 64–5
- histone deacetylase inhibitor therapies, for high-risk MDS 190
- HIV infection, as cause of myelodysplasia 38–9
- HLA-DR15, predictive factor for immunosuppressive therapy response 162, 163–4
- Hodgkin’s disease (HD) therapy, as cause of t-MDS 255–6
- HRQOL (health-related quality of life)
 - “ceiling effect” (QOL ratings higher than anticipated) 266, 267–8
 - conceptual framework 264–5, 266, 268
 - “floor effect” (QOL ratings lower than expected) 266, 267–8
 - functional status of the patient 267
 - impact of response shift as situations change 266, 267–8
 - importance of assessment 268–70
 - importance of listening to patients’ concerns 290
 - influence on decisions about interventions 268–70
 - patient involvement in treatment decisions 268–70
 - patient’s assessment of overall QOL 266, 267–8
 - patient’s general health perceptions 267
 - relationship between clinical variables and symptoms 265–6, 267
- HRQOL data from clinical trials
 - data interpretation and clinical significance 274–5
 - including QOL in study design 272, 273–4
 - measurement of symptoms and side-effects 273
 - missing QOL data 272
 - QOL component of NCCN MDS Practice Guidelines 273
 - “supportive care” not strictly defined 273
 - validity and reliability of data 272, 273–4
 - variability in timing and choice of interventions for side-effects 273
- HRQOL in MDS
 - effects of fatigue 275–6, 277
 - effects of living with uncertainty 278–9
 - effects of repeated infections 277–8
 - effects of transfusion support 276–7
 - quality of care at the end of life 279
 - quality of communication with clinicians 278–9
 - specific issues relevant to MDS patients 275–9
 - trust in clinicians 278–9
- HRQOL measurement 270–1, 272
 - Linear Analog Self Assessment 270, 271
 - qualitative instruments 270–2
 - quantitative instruments 270, 271
 - SF-36 270, 271
 - utility assessments 272
- HRQOL research in MDS
 - clinical trials 282–4, 287, 288–9
 - descriptive studies 279–81, 282

- HRQOL research in MDS (*cont.*)
 - EORTC QLQ-C30 instrument 271, 283, 288–9
 - EuroQOL Visual Analog Scale (VAS) 282–3, 284, 288–9
 - FACT-Anemia Questionnaire 284–5, 288–9
 - FACT-G (FACIT-G) study 271, 279–81, 282
 - importance of patient-reported outcomes 290
 - Mental Health Inventory (MHI) 271, 286, 288–9
 - Multidimensional Fatigue Inventory (MFI) 283, 284, 288–9
 - research to date 279–81, 284, 287, 288–9
 - SF-36 instrument 271, 282, 284, 288–9
 - Thomas Uncertainty Scale 271, 280
 - HSC *see* hemopoietic stem cells; hematopoietic stem cells
 - hypermethylation
 - marker of MDS disease progression 68–9, 74, 80–1
 - reversal by DMT inhibitors 190
 - hypocellular marrows 44–5
 - hypocellular MDS 5
 - ICL670 iron chelator, clinical trials 230–1
 - IL-3
 - see also* rIL-3
 - decreased production in MDS 210–11
 - in vitro effects on MDS cells 210–11
 - IL-6, decreased production in MDS 210–11
 - see also* rIL-6
 - imatinib mesylate (STI571, Gleevec) 75, 100–4, 115–16, 133
 - activity in CMML with chromosome 5q33 translocations 185–6
 - immune-mediated aspects of MDS
 - association with immune-mediated diseases 149
 - association with LGL marrow failure disorder 149, 151–2
 - association with SAA marrow failure disorder 149–50, 151
 - autoantigen overexpression 155–7
 - clonal T-cell expansions 154–5, 156
 - evidence for 148–50, 153, 155, 156
 - implications in bone marrow failure 147–8
 - in vitro progenitor cell inhibition 152–3
 - possible interference by immunosuppressive treatment 157–8
 - possible protective immune-mediated process 157–8
 - possible results of T-cell-mediated damage 157–8
 - response to ATG treatment 149
 - T-cell abnormalities 153–5, 156
 - T lymphocytes and bone marrow failure 152–3
 - immunologic cell dysfunction, in MDS 70–1
 - immunologic markers, for response to immunosuppressive therapy 19–20
 - immunophenotype, as a prognostic factor 17, 18–19
 - immunosuppression clinical trials in MDS 158–60, 161–2
 - ATG-based treatments 158–60, 161
 - combined treatments 159–60, 161
 - ciclosporin-based treatments 161
 - cytokine antagonists 162
 - possible interruption of protective immune-mediated process 157–8
 - possible selection for resistant clones 157–8
 - immunosuppression in SAA/MDS overlap category, clinical trial 160–1
 - immunosuppressive therapy in MDS 148
 - as cause of t-MDS/t-AML 97, 114–15, 116–17
 - ATG or CSA treatment 175–6
 - difficulties in comparing trials 164
 - for hematopoietic inhibitory T lymphocytes 175–6
 - immunologic markers for response to 19–20
 - patient selection using prognostic scoring 165
 - predictive factors for response 156, 162–4
 - prognostic scoring 162–4
 - response definition variation between trials 164
 - treatment monitoring and optimization 165
- IMRAW (International MDS Risk Analysis Workshop) 11–17
- in vitro culture systems, effects of HGFs on hematopoiesis in MDS 210–11
 - in vitro observations of HGFs as platform for clinical testing 210–11
 - infections in MDS, effects on quality of life 277–8
 - inflammatory cytokines *see* cytokines
 - Infliximab humanized monoclonal antibody, use in TNF- α inactivation studies 178–9
 - inhibitory cytokines *see* cytokines

305 Index

- interleukins *see* IL-3; IL-6; rIL-3; rIL-6; rIL-11; rILs
- International Workshop on Prognostic Factors in MDS 41–2
- IPSS (International Prognostic Scoring System) 11–12, 14, 15–16, 17
 - as framework for patient management 24
 - future directions 24–5
 - post-IPSS classification refinements 17–23
 - risk groups 11–15, 16, 17
 - risk level and choice of therapy 173–4
 - score, and choice of HCT therapy 244–5
 - score, and survival after HCT 243–4, 246
 - score, and timing of HCT 246
 - scoring of cytogenetic abnormalities 98, 99
- iron chelation 209–10
- iron chelation therapies
 - clinical trials 227–31
 - continuous subcutaneous infusion 227–9
 - deferiprone (L1, Ferriprox) 229–30
 - desferrioxamine (Desferal) 227–9
 - ICL670 230–1
 - large-volume bolus injections 227–9
 - oral iron chelators 229–31
 - to improve marrow function 70
- iron overload (transfusional)
 - cause of oxidative stress in MDS 68–9, 70
 - damaging effects of NTBI 226–9
 - due to excessive red blood cell transfusions 68–9, 70, 209–10
 - in MDS patients 209–10, 226–7, 228, 231
 - toxic effects 226–7, 228
- irradiation for HCT, as cause of t-MDS 255–6
- isotretinoin therapy
 - for high-risk MDS (IPSS intermediate-2 or high) 190–1
 - for JMML 190–1
- JCMML (juvenile chronic myelomonocytic leukemia) *see also* JMML
 - association with neurofibromatosis type 1 (NF-1) 133–4
 - in association with the Noonan syndrome 133–4
 - underlying genetic defects 133–4
- JMML(juvenile myelomonocytic leukemia) 45–6, 49–50, 51 *see also* pediatric myelodysplastic syndromes
 - and –7 chromosome abnormality 97, 110–11
 - hematopoietic cell transplantation 254–5
 - isotretinoin therapy 190–1
 - NF-1 (neurofibromin-1) gene-inactivating mutations 193
 - ras* gene mutations 193
- karyotype evolution in MDS 99–100
- karyotypes
 - abnormal forms in MDS 74–5, 96, 97–8
 - chromosome deletion anomalies 74–5
 - complex karyotypes 114
 - normal karyotype in MDS 106
- lenalidomide *see* CC-5013 (lenalidomide or Revlimid)
- leukemia induction
 - possible genetic mechanism 136
 - possible role of *EVII* gene 77
 - possible role of *MDS1/EVII* fusion gene 77
 - role of *AML1/MDS1/EVII* (AME) fusion gene 77
- LGL (large granular lymphocyte lymphoproliferative disease), association with MDS 149, 151–2
- LOH (loss of heterozygosity) studies 106–7
- lonafarnib (SCH66336, Sarasar) therapy for high-risk MDS 193–5
- marrow
 - hemopoietic cellularity increased in MDS 63
 - histopathology in MDS 44–5
 - hypocellular 44–5
 - MVD (microvascular density) increased in MDS 66–7
 - toxic effects of iron overload in MDS 226–7, 228
- marrow blast percentage, as a prognostic feature 8–9
- marrow dysfunction
 - features which impact on clinical outcome 17–23
 - implications of immune-mediated responses 147–8
 - latency period 104–5
 - pathogenesis of 63
- marrow fibrosis in the MDS 44–5

- marrow microenvironment
 - abnormal functions in MDS 182–4
 - effects of inflammatory and inhibitory cytokines 64, 65–6
 - increased apoptosis in MDS 65, 67–9, 71
 - ineffective hemopoiesis in MDS 65, 67–9, 71
 - oxidative stress damage in MDS 65, 67–9, 71
 - secondarily acquired inhibitory features 65, 67–9, 71
 - stromal abnormalities 63–4, 65, 68–9, 71
 - suboptimal stromal hemopoietic support in MDS 66
- marrow progenitor cells, in vitro studies with rTPO 225
- M-CSF, decreased production in MDS 210–11
- MDS (myelodysplastic syndromes) *see also* t-MDS (secondary/therapy-related MDS)
 - characteristics 1–3, 209–10
 - clinical variants 5–6
 - common features with β -thalassemia major 226–7
 - de novo 1
 - evidence for immune-mediated process 148–50, 153, 155, 156
 - evolution into acute myeloid leukemia (AML-MDS) 1, 68–9, 74–5, 80–1
 - FAB morphologic classification 1–3
 - hypocellular MDS 5
 - implications of immune-mediated mechanism 148
 - increasing incidence with age 65, 68–9, 81–2
 - morphologic classifications 1–6
 - multigenic nature 68–9, 74, 79, 82–3
 - myelonic clonogenic abnormalities similar to AML 71–2
 - patterns of disease 99–100
 - prediction of disease risk using gene expression analysis 139–40, 141
 - production of antigens which induce T-cell responses 155–7
 - rate of progression 1
 - recommendations on use of morphologic criteria 4–5
 - search for underlying causes 129, 130
 - with fibrosis 5
 - with myelofibrosis 44–5
 - WHO morphologic classification 3–5
 - MDS-AML, therapy-related 43–5
 - MDS/MPD (myelodysplastic/myeloproliferative diseases) 45–8, 50, 51
 - MDS unclassified, WHO classification 3–5, 42
 - MDS1/EVII* fusion gene, possible role in leukemia induction 77
 - melphalan therapies, for high-risk MDS (IPSS intermediate-2 or high) 187
 - methylation silencing of genes 136
 - and leukemia transformation risk 68–9, 74, 80–1
 - microarray analysis of gene expression in MDS 136–7, 140, 141
 - prediction of disease risk using CD34+ cells 139–40, 141
 - selection of differentially expressed CD34+ genes 138–9
 - technique 137–8
 - to assess global gene expression profiles 131
 - mitochondria
 - activation of apoptotic pathway 213–14
 - dysfunction due to oxidative stress 67–9, 71
 - role in apoptotic signaling pathway 72–3
 - MLL* (mixed lineage leukemia) gene (*ALL1*, *HTRX*, *HRX*) 113–14
 - MMPs (matrix metalloproteases)
 - and abnormal stromal function in MDS 182–4
 - selective inhibition by AG3340 (Prinomastat) 182–4
 - molecular abnormalities
 - altered gene expression 17, 20–3
 - altered levels of signal transduction molecules 68–9, 74, 75–7, 78–9
 - association with specific syndromes in MDS 132–5
 - effects on disease progression and prognosis 78–9
 - indications of chromosomal and genetic instability 78–9
 - multistep/multigenic model of pathogenesis 68–9, 74, 79
 - related to genetic alterations 68–9, 74, 75–7, 78–9
 - role of transcription factors in signaling pathways 68–9, 74, 78–9
 - telomere dynamics 17

307 Index

- molecular models
 - for chromosome abnormalities 104–5
 - for loss of gene function 104–5
- morphologic classifications of MDS
 - FAB 33, 34, 37
 - WHO 35, 36, 37
- morphologic criteria, recommendations on use of 4–5
- morphologic features used to diagnose MDS 39
 - blast percentage in blood and marrow 38
 - evaluation of myeloid cell lines 35
 - manifestations of dyserythropoiesis 35
 - manifestations of dysgranulopoiesis 38
 - megakaryocytic dysplasia 38
 - myelodysplasia not diagnostic of MDS 38–9
 - non-clonal etiologies of myelodysplasia 38–9
 - peripheral blood abnormalities 35
- MPD (myeloproliferative disorder) 2–3
- multistep/multigenic model of MDS and AML
 - pathogenesis 68–9, 74, 79, 82–3
- MVD (microvascular density)
 - as a prognostic feature 17, 18
 - in MDS marrow 66–7
 - increase relates to progression in MDS 179–80
- myeloblasts, role in medullary
 - angiogenesis 179–80
- myelodysplasia
 - non-clonal etiologies 38–9
 - not diagnostic of MDS 38–9
- myelodysplastic syndromes *see* MDS
- myelodysplastic/myeloproliferative diseases (MDS/MPD) 45–8, 50, 51
- myelofibrosis in the MDS 5, 44–5
- myeloid leukemia in Down syndrome 51–2, 53
- myelonic clonogenic abnormalities, similarities in MDS and AML 71–2
- myeloproliferative diseases *see*
 - myelodysplastic/myeloproliferative diseases (MDS/MPD)
- National Comprehensive Cancer Network (NCCN) guidelines
 - anemia evaluation and treatment 211–13
 - hemopoietic cytokines support for refractory cytopenias 212–13
 - iron chelation therapy 213
 - quality of life (QOL) component 273
 - red blood cell and platelet transfusions 211–13
 - supportive care 211–13
- neutropenia, congenital, associated with MDS 134
- NF-1 (neurofibromatosis type 1)
 - association with JCMML 133–4
 - in children 49–51
- NF1* (neurofibromin-1) gene, inactivating mutations in JMML 193
- NMA (non-myeloablative) conditioning regimens for HCT 250–2, 253
- NMA (non-myeloablative) transplant 244–5
- non-Hodgkin’s lymphoma (NHL) therapy, as cause of t-MDS 255–6
- N-ras* *see* *ras* gene mutations
- NTBI (non-transferrin-bound iron), damaging effects of 226–9
- oligonucleotide microarray technique 130, 137–8
- oxidative stress/damage
 - accumulated damage with aging 65, 68–9, 81–2
 - cause of damage in MDS marrow 65, 67–9, 71
 - caused by iron overload 68–9, 70
 - effects of NTBI due to iron overload 226–9
 - TNF- α inactivation therapies 176–9
- oxygen free radical production in MDS 65, 67–9, 71
- P-glycoprotein inhibitor therapies, for high-risk MDS (IPSS intermediate-2 or high) 187–8, 193
- p15INK4b* gene
 - hypermethylation in MDS and leukemias 17, 20, 22–3, 68–9, 74, 80–1
 - silencing by hypermethylation 136
- p16INK4a* gene, hypermethylation in MDS and leukemias 68–9, 74, 80–1
- p38* kinase signaling cascade, and hemopoietic suppression 67, 68–9
- p53* gene mutations, effects of 76–7, 135–6
- paroxysmal nocturnal hemoglobinuria *see* PNH
- parvovirus B19 infection, as cause of myelodysplasia 39
- pathogenesis of AML, multistep/multigenic model 68–9, 74, 79

- pathogenesis of MDS
 - alterations in gene function 100–3, 104
 - AML1* gene point mutations 77
 - cytogenetic abnormalities 74–5
 - effects of aging 65, 68–9, 81–2
 - epigenetic hypermethylation 68–9, 74, 80–1
 - Ets* family of transcription factors 68–9, 74, 78–9
 - fms* mutations 76
 - loss of gene function 104–5
 - multigenic nature 68–9, 74, 79, 100–3, 104
 - multistep process 68–9, 74–5, 79, 129, 130
 - p53* gene mutations 76–7
 - ras* gene mutations 75–6
 - telomere dysfunction 68–9, 79–80
- pathogenesis of MDS marrow dysfunction 63
 - inherent hemopoietic stem cell (HSC) abnormalities 65, 68, 69, 71–4, 82
 - microenvironmental stromal abnormalities 63–4, 65, 68, 69, 71
- PBPC (G-CSF-mobilized peripheral blood progenitor cells), use in HCT 247–8, 253
- PDF-receptor fusion genes 185–6
- pediatric myelodysplastic syndromes 51–2, 53
 - see also JCMML; JMML
 - AML, hematopoietic cell transplantation 254–5
 - MDS, hematopoietic cell transplantation 254–5
 - monosomy 7 syndrome 97, 110–11
 - NF-1 (neurofibromatosis type 1) 49–51, 133–4
 - occurrence of –7/del(7q) abnormalities in MDS 97, 110–11
 - WHO proposed classification 51–2, 53
- pentoxifylline 100–4
 - use in TNF- α inactivation studies 178
- phenylbutyrate therapy, for high-risk MDS 190
- platelet-derived growth factor receptor- β translocations 115–16
- PNH (paroxysmal nocturnal hemoglobinuria)
 - abnormalities in MDS and SAA 149–50, 151
 - abnormalities predict response to ATG 149–51
 - myelodysplastic features 38–9
 - predictive factor for immunosuppressive therapy response 162–4
 - posttransplant relapse in MDS 256–7
- prognosis for MDS 6–7, 10, 12, 14, 15–16, 17
 - 5q– syndrome 8–9
 - age of patient 11–14, 15–17
 - ALIP 9, 17, 18
 - alkylating agent and/or radiation-related MDS 43–4
 - AML1* gene point mutations 77
 - angiogenesis 17, 18
 - biologic assessment 9–10, 17
 - chromosome abnormalities 11–12, 17
 - combined assessment system 11
 - complex karyotypes 114
 - cytogenetic abnormalities associated with MDS 43, 96, 97–8
 - cytogenetic abnormalities scoring 98, 99
 - cytogenetic risk groups 11–12, 17, 18
 - cytopenias 11–17
 - factors affecting transformation to AML 9–11, 14, 15
 - features of MDS marrow 17–23
 - flt3* gene mutations 77
 - gene expression alterations 17, 20–3
 - gene expression profiles associated with risk groups 139–40, 141
 - gene mutations present 8
 - immunologic markers 19–20
 - in vitro hemopoietic clonogenic assays 9–10, 11
 - IPSS (International Prognostic Scoring System) 11–12, 14, 15–16, 17–23
 - marrow blast percentage 8–9, 11–17
 - marrow histopathology 44–5
 - marrow immunophenotypic analyses 17, 18–19
 - microarray analysis 139–40, 141
 - molecular abnormalities 17, 20–3, 78–9
 - morphologic assessment: FAB 6–7, 8
 - morphologic assessment: WHO 8–9
 - morphologic features 17, 18–23
 - ras* and *fms* mutation status 76
 - t-MDS (secondary/therapy-related MDS) 43–5
 - telomere dynamics 17, 23
 - topoisomerase II inhibitor-related MDS 43–4
- prognostic classification systems 98, 99
 - as framework for patient management 24
 - future directions 24–5

prognostic scoring systems, use of cytogenetic findings 96–7

PTK787, RTK inhibitor 182–3, 184

QOL (quality of life) *see also* HRQOL (health-related quality of life)
attempts to define 263
conceptual frameworks 263–4, 265, 266, 268
traditional biomedical model for health care 263–4

quinine (Pgp modulator) therapy, for high-risk MDS 187–8

R115777 (tipifarnib, Zarnestra) therapy, for high-risk MDS (IPSS intermediate 2 or high) 194

RA (refractory anemia)
ambiguity in FAB classification 40–1
FAB classification 1–3, 33, 34
WHO classification 3–5, 40

radiation therapy-related MDS (t-MDS) 43–5

RAEB (refractory anemia with excess blasts), FAB classification 1–3, 33, 34

RAEB 1 (refractory anemia with excess blasts, category 1), WHO classification 3–5, 41–2

RAEB 2 (refractory anemia with excess blasts, category 2), WHO classification 3–5, 41–2

RAEB-T (refractory anemia with excess blasts in transformation) 3–5
FAB classification 1–3, 33, 34, 41–2

RARS (refractory anemia with ringed sideroblasts) 41
FAB classification 1–3, 33, 34
WHO classification 3–5

ras gene mutations
alteration of signal transduction 135–6
effects of 75–6, 192–3
in CMML 192–3
in JMML 193
in MDS 100–3, 104, 192–3
involvement in pathogenesis of MDS 75–6

ras pathways, deregulation linked with –7
chromosome abnormality 110–11

RCMD (refractory cytopenia with multilineage dysplasia), WHO classification 3–5, 40–1

RCMD-RS (refractory cytopenia with multilineage dysplasia and ringed sideroblasts), WHO classification 40–1

refractory cytopenias, supportive care for 209–10

rEPO (recombinant erythropoietin)
therapy 209–10 *see also* EPO
and *all-trans* retinoic acid combined treatment 223
and amifostine combined treatment 223
and rGM-CSF combined treatment, clinical trials 222
and rIL-3 combined treatment 223
clinical aim of treatment 214–17
mechanisms of action 213–14
NCCN guidelines for refractory cytopenia support 212–13
rationale of treatment 214–17
response rates and durability in clinical trials 214–15, 217

rEPO and rG-CSF combined treatment
clinical trials 218–19, 220
long-term follow-up data 220, 221
Nordic MDS Group studies 220, 221
prediction of erythroid response 218–19, 220

Revlimid *see* CC-5013 (lenalidomide or Revlimid)

rG-CSF (recombinant granulocyte colony-stimulating factor) therapy 209–10 *see also* G-CSF
clinical trials 218–19, 220
inhibition of mitochondrially activated apoptosis 213–14
long-term follow-up data 221–22
mechanisms of action 213–14
NCCN guidelines for refractory cytopenia support 212–13
Nordic MDS Group studies 221–22
patient responses in clinical trials 217–18
prediction of erythroid response 218–19, 220
synergy with rEPO 213–14

rGM-CSF (recombinant granulocyte–macrophage colony-stimulating factor) *see also* GM-CSF
clinical trials 221–2
effects on neutrophil counts 221–2
patient responses in clinical trials 221–2

- rGM-CSF and rEPO combined treatment
 - clinical trials 222
 - NCCN guidelines for refractory cytopenia support 212–13
- rHGFs (recombinant hematopoietic growth factors) 209–10 *see also* HGFs
 - in combination therapies 231
- RIC (reduced-intensity conditioning)
 - regimens for HCT 250–2, 253
 - transplant 244–5
- rIL-3 (recombinant interleukin-3)
 - and rEPO combined treatment 223
 - studies 223
- rIL-6, clinical trials 223–4
- rIL-11
 - clinical trials 224
 - platelet responses in MDS patients 224
- rILs (recombinant interleukins) 223–4
- rMGDF (recombinant megakaryocyte growth and development factor)
 - clinical trials in MDS and AA patients 226
 - in vitro studies on bone marrow progenitor cells 225
- rTPO (recombinant thrombopoietin, *c-mpl* ligand) *see also* TPO
 - clinical trials in MDS and AA patients 226
 - in vitro studies on bone marrow progenitor cells 225
 - potential to foster leukemic cell growth in MDS 225
 - to reduce thrombocytopenia after chemotherapy 224–5
- SAA (severe aplastic anemia) *see also* AA (aplastic anemia)
 - association with MDS 149–50, 151
 - ATG treatment 147–8
 - indications of immune-mediated mechanism 147–8
- SAA/MDS overlap category, clinical trial of immunosuppressive treatment 160–1
- secondary AML *see* t-AML
- secondary MDS *see* t-MDS
- signal transduction pathways
 - alteration due to genetic mutations 135–6
 - alteration to normal flow 68, 69, 74, 75–7, 78–9
- small-molecule inhibition of VEGF RTK 182–3, 184
- stroma, abnormal function in MDS related to
 - MMPs 182–4 *see also* marrow microenvironment
- SU11248, RTK inhibitor 182–3, 184
- SU5416, RTK inhibitor 182–3, 184
- supportive care *see also* QOL (quality of life)
 - for anemia 209–10
 - for refractory cytopenias 209–10
 - future directions 231
- t-AML (secondary/therapy-related AML) 5–6, 43–5 *see also* AML
 - as a consequence of cancer therapy 97, 114–15, 116–17
 - assessing risk of development 104–5
 - due to exposure to cytotoxic agents 97, 114–15, 116–17
- T cells
 - abnormalities 153–5, 156
 - hematopoietic inhibitory T lymphocytes 175–6
 - responses to antigens produced by MDS cells 155–7
- t-MDS (secondary/therapy-related MDS) 1, 5–6, 43–5
 - assessing risk of development 104–5
 - caused by cancer therapy 97, 114–15, 116–17
 - caused by irradiation and chemotherapy for other disorders 255–6
 - caused by therapy for Hodgkin’s disease 255–6
 - caused by therapy for non-Hodgkin’s lymphoma 255–6
 - common cytogenetic findings 97, 114–15
 - due to exposure to cytotoxic agents 97, 114–15, 116–17
 - hematopoietic cell transplant (HCT) treatment 255–6
- TBI (total body irradiation)-based HCT conditioning regimens 247–50
- telomere dynamics, and genomic instability 17, 23
- telomeres
 - abnormal maintenance in MDS 68, 69, 79–80
 - effects of *p53* mutations in MDS 68, 69, 79–80

311 Index

- β -thalassemia major
 - clinical trials of iron chelators 227–31
 - common features with MDS 226–7
 - effects of transfusional iron overload 226–7
- thalidomide (Thalomid) 100–4
 - antiangiogenic studies 180–1, 182
 - TNF-inhibitory properties 180–1, 182
- thalidomide analogues *see* CC-5013
 - (lenalidomide or Revlimid)
- therapies for high-risk MDS (IPSS intermediate-2 or high) 183, 185–93, 195
 - 5-aza-2-deoxycytidine (decitabine; Dacogen, Supergen) 190
 - 5-azacitidine (5-AzaC; Vidaza, Pharmion) 190
 - action of imatinib in CMML+Eos 185–6
 - chemotherapy 188, 193
 - ciclosporin-A (Pgp inhibitor) 187–8, 193
 - cytarabine 186, 187–8, 193
 - depsipeptide 190
 - differentiation agents 190–1
 - DMT inhibitors 190
 - epigenetic gene regulation reversal 190
 - farnesyl transferase inhibitors (FTI) 192–3, 195
 - gemtuzumab ozogamicin (Mylotarg) 186–7
 - histone deacetylase inhibitors 190
 - isotretinoin 190–1
 - lonafarnib (SCH66336, Sarasar) 193–5
 - melphalan 187
 - P-glycoprotein inhibitors 187–8, 193
 - phenylbutyrate 190
 - promising agents under clinical investigation 183, 185
 - quinine (Pgp modulator) 187–8
 - R115777 (tipifarnib, Zarnestra) 193–4
 - targeting PDF-receptor and FGF-receptor fusion genes 185–6
 - TLK199 selective inhibitor of GST P1–1 191
 - topoisomerase inhibitors 186
 - topotecan and cytarabine 186
 - trichostatin A 190
 - valproic acid 190
- therapies for low and intermediate-1 (IPSS) risk MDS 174–85
 - angiogenesis inhibitors 179–80, 181, 185
 - immunosuppressive therapy 175–6
 - small-molecule inhibition of VEGF RTK 182–3, 184
 - targeting biological effectors of ineffective hematopoiesis 174–85
 - targeting hematopoietic inhibitory T lymphocytes 175–6
 - thalidomide (Thalomid) and analogues 180–1, 182
 - TNF- α inactivation 176–9
- therapies for MDS
 - present range of treatments and future hopes 173
 - risk level and choice of therapy 173–4
- therapy-related acute myeloid leukemia *see* t-AML
- therapy-related MDS *see* t-MDS
- TLK199
 - selective inhibitor of GST P1–1 191
 - therapy for high-risk MDS 191
- TNF- α inactivation studies 176–9
 - amifostine 176–8
 - Etanercept (Enbrel) recombinant soluble TNF- α 178–9
 - Infliximab humanized monoclonal antibody 178–9
- topoisomerase II inhibitor-related MDS 43–4
- topoisomerase inhibitor therapy, for high-risk MDS 186
- topotecan and cytarabine therapy, for high-risk MDS 186
- TPO (thrombopoietin, *c-mpl* ligand) *see also* rMGDF; rTPO
 - biologic studies 224–5
 - clinical trials in MDS and AA patients 226
 - combination treatments with cytokines 224–5
 - hematopoietic growth factor 224–5
 - plasma levels in MDS 224–5
 - reduced numbers of receptors (*c-mpl*) in MDS 224–5
 - rMGDF in vitro studies on bone marrow progenitor cells 225
- transcription factors
 - and control of gene expression 68, 69, 74, 78–9
 - roles in signaling pathways 68, 69, 74, 78–9
- transcriptional silencing 104–5

- transfusion support in MDS
 - basis for decision to transfuse a patient 276–7
 - quality-of-life (QOL) effects 276–7
- transfusional iron overload in MDS *see* iron overload
- transfusional siderosis 68, 69, 70 *see also* iron overload
- translocations *see* chromosome translocations
- trichostatin A therapy, for high-risk MDS 190
- trisomy 8, possible selection by immune pressure 157–8
- trisomy-8 disease
 - ATG treatment response 154–5
 - clonal T-cell expansions 154–5, 156
- tumor suppressor genes
 - mechanisms of inactivation 132
 - silencing by DNA methylation (epigenetic hypermethylation) 68, 69, 74, 80–1, 136
- uncertainty, emotional effects of living with MDS 278–9
- valproic acid therapy, for high-risk MDS 190
- VEGF (vascular endothelial growth factor)
 - and ALIP 66–7
 - angiogenic peptide 66–7
 - levels in AML patients 66–7
 - role in angiogenesis 179–80, 185
- VEGF-A inhibitors, bevacicumab (Avastin) 184
- VEGF RTK, small-molecule inhibition of 182–3, 184
- vitamin deficiencies, as cause of myelodysplasia 39
- WHO (World Health Organization) morphologic classification of MDS 3–5, 35, 36, 37, 40–2
 - q– syndrome 40
- CMML (chronic myelomonocytic leukemia) 45–6, 47–8, 49
- differences to FAB classification 40–2
- JMML (juvenile myelomonocytic leukemia) 49–50, 51
- MDS/MPD
 - (myelodysplastic/myeloproliferative diseases) 45–6
- MDS – unclassified 42
- pediatric myelodysplastic syndromes
 - (proposed classification) 51–2, 53
- RA (refractory anemia) 40
- RAEB 1 (refractory anemia with excess blasts, category 1) 41–2
- RAEB 2 (refractory anemia with excess blasts, category 2) 41–2
- RARS (refractory anemia with ringed sideroblasts) 41
- RCMD (refractory cytopenia with multilineage dysplasia) 40–1
- RCMD-RS (refractory cytopenia with multilineage dysplasia and ringed sideroblasts) 40–1
- WT1 (Wilms tumor) antigen, overexpression in MDS 155–7
- WT1 (Wilms tumor) suppressor gene, increased expression as disease progresses 77
- Y chromosome loss (–Y) in MDS 106